At Cancer Care Associates, we believe in the power of cancer research and the hope it gives to millions of patients worldwide. In fact, we have more patients involved with national and pharmaceutical clinical trials than any other cancer treatment center in the central valley. Our participation in this research has improved cancer care for people in our geographic region and around the world. These clinical trials cover a broad spectrum of diagnosis and include cancer, non-cancer, prevention and symptom management studies.
Cancer Care Associates is dedicated to cancer research with ongoing clinical trials with specific departments focused solely on these studies. By participating in these clinical trials, Cancer Care Associates has privileged access to treatment options that would not otherwise be available. Implementing the proper techniques with world-renowned research institutions is another example of Cancer Care Associates committment to treatment. These leading edge therapies significantly increase treatment options for our patients, which aide in the plight against cancer. These trials not only have a direct benefit on our patients’ health, but they deliver positive results which can be shared and utilized in clinics worldwide. We take pride in our ongoing clinical trials with various research groups such as the prestigious Mayo Clinic. It is our quest to continually strive to reduce the number of cancer patients, deliver the most advanced forms of procedures and promote novel approaches to ongoing treatment.
Cancer Care Associates are members of the following research groups:
• NCCTG (North Central Cancer Treatment Group affiliate through
The Mayo Clinic)
http://ncctg.mayo.edu/
• VEEDA Oncology
http://www.veedaoncology.com/
Cancer Care Associates are currently involved in clinical trials concerning breast cancer, colorectal cancer, head and neck cancers, lung cancer and ovarian cancer, as well as studies focusing on pain control and sleep improvement.
Cancer Care Associates Trials Open to Accrual
Breast
PACCT-1: A randomized study of hormonal treatment vs hormonal plus chemotherapy treatment for patients that are ER+ and/or PR+, HER 2 negative, node negative breast cancer (1.1-5 cm tumor)
CALGB 40101: A randomized trial of adjuvant adriamycin and cytoxan for 4 cycles vs Paclitaxel for 4 cycles for women with 0-3 positive nodes or high risk
NSABP B-40: A randomized trial of neoadjuvant treatment of adding capcitabine or gemcitabine to docetaxel when given prior to adriamycin and cytoxan, with or without Bevacizumab, in women with palpable or operable cancer
BOLERO-2: A randomized study of Exemestane +/- Everolimus in the treatment of women who are past menopause with estrogen receptor positive locally advanced or metastatic breast cancer that is refractory to letrozole or anastrozole.
AMGEN 20060359 D-CARE: A Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence.
Colon Cancer/Rectal Cancer
NSABP R-04: A Randomized study comparing preoperative radiation therapy and capcitabine with or without oxaliplatin to preoperative radiation therapy and continous infusion 5FU with or without oxalipatin for patients with operable rectal cancer
Lung Cancer
V-08-030: Darbepoetin Alfa every 3 weeks in anemic patients with advanced NSCLC receiving multi cycle chemotherapy
GERON CP14B012: A Phase 2 Study of Imetelstat as Maintenance Therapy after Initial Induction Chemotherapy for Advanced Non-Small Cell Lung Cancer.
Melanoma
H8K-MC-JZAO: randomized study of Tasisulam vs Paclitaxel as second line treatment in patients with Metastatic Melanoma
Lymphoma
RATE: A study using rituximab with a faster infusion time for previously untreated patients with diffuse large B-cell or follicular non-hodgkins lymphoma.
REGISTRY TRIALS
Breast
VIRGO: Locally recurrent or metast. Breast Ca. receipt of 1st. systemic cytotoxic chemo and/or targeted therapy among those with Her-2 normal diseasea or 1st hormone TX among those w/HR+disease for TX of locally recurrent or mets. Disease no greater than 1 month prior to enrollment
MDS
MORE REGISTRY: Iron overloaded, lower risk Myelodysplastic patients registry.
HEAD AND NECK CANCER
LORHAN: Prospective, Longitudinal, Multi-Center Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma.
